Skip to main content

Table 1 Patient characteristics

From: Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer

Characteristic Baseline model Chemotherapy response-based model
N Percent (%) N Percent (%)
Gender
 Female 125 (38.7) 89 (38.2)
 Male 198 (61.3) 144 (61.9)
Age (year)
  ≤ 56 169 (52.3) 129 (55.4)
 >56 154 (47.7) 104 (44.6)
KPS
 70 ~ 80 95 (29.4) 86 (36.9)
 90 ~ 100 228 (70.6) 147 (63.1)
Number of organ metastases
 0 55 (17.0) 33 (14.2)
 1 195 (60.4) 145 (62.2)
  ≥ 2 73 (22.6) 55 (23.6)
Liver metastases
 Absent 74 (22.9) 48 (20.6)
 Present 249 (77.1) 185 (79.4)
Baseline WBC (×1000/mm3)
  ≤ 6.39 162 (50.2) 113 (48.5)
  > 6.39 161 (49.8) 120 (51.5)
Baseline N
  ≤ 0.665 162 (50.2) 113 (48.5)
  > 0.665 161 (49.8) 120 (51.5)
Baseline LDH
  ≤ 159 155 (48.0) 116 (49.8)
  > 159 168 (52.0) 117 (50.2)
Baseline CEA
  ≤ 7.32 161 (49.8) 115 (49.4)
  > 7.32 162 (50.2) 118 (50.6)
Baseline CA 19–9
  ≤ 1453 162 (50.2) 112 (48.1)
  > 1453 161 (49.8) 121 (51.9)
Change in LDH level at week 6 NI  
 Decrease   80 (34.3)
 No change or increase   153 (65.7)
Change in CEA level at week 6 NI  
 Decrease   93 (39.9)
 No change or increase   140 (60.1)
Change in CA 19–9 level at week 6 NI  
 Decrease   151 (64.8)
 No change or increase   82 (35.2)
LDH at week 6 NI  
  ≤ 170.7   113 (48.5)
  > 170.7   120 (51.5)
CEA at week 6 NI  
  ≤ 7.97   117 (50.2)
  > 7.97   116 (49.8)
CA 19–9 at week 6 NI  
  ≤ 790.7   114 (48.9)
  > 790.7   119 (51.1)
Alb level at week 6 NI  
  ≤ 39.0   117 (50.2)
  > 39.0   116 (49.8)
Initial response to chemotherapy NI  
 PD   55 (23.6)
 Non-PD   178 (76.4)